In a significant disclosure at the 2026 Boao Asia Forum, Chen Jiehui (陈杰辉), Vice Chairman and General Manager of Guangzhou Pharmaceutical Group (广药集团), outlined an ambitious blueprint to position the state-owned pharmaceutical giant at the forefront of global healthcare innovation. The strategy hinges on two parallel tracks: a substantial investment to streamline the overseas expansion of traditional Chinese medicine (TCM) and a concerted push to achieve global parallel in the high-stakes nuclear medicine track. This move signals a profound shift for one of China’s oldest drugmakers, from a domestic-focused entity to an innovation-driven global competitor.
Executive Summary:
- Guangzhou Pharmaceutical Group is committing RMB 10 billion to establish a Hengqin Intelligent Manufacturing Center, creating an integrated model for TCM registration, production, and global distribution.
- The company is deploying a four-part strategy to overcome extreme barriers in the nuclear medicine sector, aiming to compete directly with global leaders like Novartis and AstraZeneca.
- Strategic alliances with Qinshan Nuclear Power, GE Healthcare, and top Chinese research institutions are crucial for securing isotope supplies and accelerating R&D.
- Through a national technology transfer center, Guangzhou Pharmaceutical is industrializing breakthrough cell and gene therapy (CGT) projects from universities like Peking University and Tsinghua University.
- The dual strategy leverages unique policy synergies within the Guangdong-Hong Kong-Macau Greater Bay Area, offering a template for Chinese pharma’s global ambitions.
Guangzhou Pharmaceutical’s Dual-Pronged Assault on Global Markets
The 2026 Boao Asia Forum served as a platform for Chinese corporate leaders to signal strategic intent, and Chen Jiehui’s announcements were among the most consequential for the healthcare sector. Guangzhou Pharmaceutical, a behemoth with deep roots in traditional remedies, is now explicitly targeting two of the most dynamic and challenging arenas in global pharma: complex biologics and precision radiopharmaceuticals. This reflects a broader trend under China’s “15th Five-Year Plan,” where state-backed champions are urged to move up the value chain and reduce dependency on imported advanced therapies.
The Hengqin Hub: A New Model for Traditional Chinese Medicine出海
Chen Jiehui candidly addressed the perennial hurdles for TCM globalization. “The出海 of traditional Chinese medicine faces two core difficulties: cultural recognition and registration procedures,” he stated. The group’s innovative solution is to leverage the complementary advantages of Macau and Hengqin within the Greater Bay Area. Macau, designated as a core area for the “1+4” strategy of appropriate economic diversification, offers a simplified approval pathway for Chinese medicines. Adjacent Hengqin provides the physical space, advanced manufacturing capabilities, and policy support for industrial scale-up.
The envisioned model is succinct: “Register in Macau, produce in Hengqin, sell within the Greater Bay Area, and export globally.” This integrated chain is designed to become a replicable template. To operationalize this, Guangzhou Pharmaceutical is investing approximately RMB 10 billion to build a state-of-the-art医药智造中心 (Intelligent Medicine Manufacturing Center) in Hengqin. The center will focus on high-standard production to meet international regulatory requirements, a critical step for markets in Europe and North America that demand stringent quality controls.
Current export successes provide a foundation. Products like Huatuo Zaizao Wan (华佗再造丸) are already sold in 29 countries, while Angong Niuhuang Wan (安宫牛黄丸) has achieved registration in Vietnam. The next phase targets Portuguese-speaking nations—leveraging Macau’s historical ties—and Southeast Asia. For Europe, Chen Jiehui emphasized a science-forward approach: “We are using the language of modern and evidence-based medicine to explain the mechanisms of TCM.” An example is the promotion of Guangyao-brand Lingzhi Spore Oil through a German partner, framing its benefits within a Western pharmacological context.
Breaking into the High-Barrier Nuclear Medicine Track
If TCM represents the fortified core business, nuclear medicine is the ambitious new frontier. Radiopharmaceuticals are indispensable for advanced diagnostic imaging and targeted radionuclide therapy, particularly in oncology. However, this sector has been dominated by multinationals due to formidable technological and regulatory barriers. Chen Jiehui articulated a clear goal: “We are striving to be on the same starting line as international front-runners in this round of competition.” He believes the global nuclear medicine track is still in a rapid growth phase, offering a window for Chinese players to achieve a “弯道超车” (overtaking on the curve).
This ambition is not mere rhetoric. It is underpinned by a systematic deconstruction of the nuclear medicine value chain and targeted actions at each node. The strategy directly addresses the four critical links Chen identified: isotope raw materials, drug R&D and production, circulation and distribution, and clinical hospital use. Success in the nuclear medicine track requires mastery of this entire ecosystem, and Guangzhou Pharmaceutical is mobilizing resources accordingly.
Deconstructing the Nuclear Medicine Value Chain: A Four-Part Framework
The complexity of the nuclear medicine track cannot be overstated. Radiopharmaceuticals often have short half-lives, necessitating a seamless, rapid pipeline from production to patient. Guangzhou Pharmaceutical’s strategy involves building or accessing capabilities at every stage, creating a closed-loop system that can compete on reliability and speed.
Securing the Lifeline: Isotope Raw Material Partnerships
The entire nuclear medicine track begins with a stable supply of radioactive isotopes. China possesses a key strategic asset: the heavy water reactor at the Qinshan Nuclear Power Plant (秦山核电), which is uniquely suited for producing certain medical isotopes. Guangzhou Pharmaceutical has established cooperation with Qinshan and the Dongjiang Laboratory (东江实验室) to secure upstream resources. This move mitigates a critical dependency on imported isotopes, which can be subject to geopolitical and supply chain disruptions. For investors, control over this scarce input is a significant competitive moat.
Accelerating R&D and Production through Strategic Alliances
Developing and manufacturing radiopharmaceuticals requires specialized expertise and infrastructure. Rather than building everything from scratch, Guangzhou Pharmaceutical is pursuing an aggressive partnership and M&A strategy. A landmark agreement was signed with GE Healthcare (GE医疗) to establish an industry-academia-research transformation center. This collaboration aims to fast-track the development and commercialization of novel nuclear medicines, leveraging GE’s global imaging expertise and Guangyao’s domestic market reach and manufacturing prowess. Such alliances are essential for compressing the innovation timeline in the fast-evolving nuclear medicine track.
Solving the Logistics Puzzle: Distribution and Clinical Integration
The “last mile” is arguably the most challenging in the nuclear medicine track. The short shelf-life of many products demands a hyper-efficient distribution network. Here, Guangzhou Pharmaceutical has secured a first-mover advantage: its subsidiary, Guangzhou Pharmaceutical Co., Ltd. (广州医药股份有限公司), obtained the first radioactive drug distribution license in Guangdong Province. This license is a regulatory green light to handle the logistics of these sensitive materials.
On the clinical front, the company is working with the Guangzhou Municipal Health Commission and institutions like The First Affiliated Hospital of Jinan University (暨南大学第一附属医院) to streamline hospital adoption. This involves training, protocol development, and ensuring the availability of necessary imaging and therapy equipment. By actively facilitating the “last kilometer,” Guangzhou Pharmaceutical reduces a major adoption barrier for its future nuclear medicine portfolio.
Beyond Radiopharmaceuticals: The Cell and Gene Therapy Ambition
Guangzhou Pharmaceutical’s innovation drive extends beyond the nuclear medicine track into the equally promising realm of cell and gene therapy (CGT). Peng Wei (彭伟), the group’s R&D lead, provided insights into the “National University Biopharmaceutical Technology Transfer Center” (全国高校生物医药技术转移转化中心). Initiated by the Ministry of Education, this center aims to commercialize breakthrough research from China’s top universities in CGT and AI-assisted drug design.
In less than a year, the center has attracted 33 projects, with 60% focused on CGT. The project pipeline includes research from Peking University (北大), Tsinghua University (清华), and Fudan University (复旦). This gives Guangzhou Pharmaceutical privileged access to cutting-edge science, positioning it as a conduit between academia and the market.
A Gene Therapy Breakthrough: Restoring Hearing in Children
Peng Wei shared a compelling case study that underscores the transformative potential of this strategy. One project targets congenital deafness caused by an OTOF gene mutation. The therapy involves injecting a functional copy of the gene directly into a child’s cochlea. “A single injection can restore hearing from a threshold of 120-130 decibels to around 20 decibels,” Peng explained. The earliest treated patient has maintained this improved hearing for nearly three years. This example illustrates how Guangzhou Pharmaceutical is moving from small-molecule generics and TCM to potentially curative advanced therapies, fundamentally altering its growth profile.
Policy Synergies: The Greater Bay Area as a Strategic Springboard
None of Guangzhou Pharmaceutical’s ambitious plans would be feasible without the unique policy environment of the Guangdong-Hong Kong-Macau Greater Bay Area. This region is being developed as an integrated innovation and economic hub, with specific provisions to foster the healthcare industry.
Macau’s Role as a Regulatory Bridgehead
Macau’s status as a Special Administrative Region with its own legal system provides a critical testing ground. Its simplified registration process for Chinese medicines, aligned with international standards, offers a faster route to market for TCM products destined for overseas. By registering products in Macau first, Guangzhou Pharmaceutical can generate clinical and usage data that supports subsequent applications in other jurisdictions, effectively using Macau as a regulatory gateway.
Hengqin: The Manufacturing and Export Engine
The Hengqin New Area, adjacent to Macau, is central to the physical execution of the strategy. It offers tax incentives, cross-border data flow facilitation, and streamlined customs procedures under the “Co-operation Zone” framework. The planned RMB 10 billion Intelligent Manufacturing Center here will not only produce TCM but is also envisioned to eventually manufacture advanced therapies like nuclear medicines and CGT products for global export. This geographical布局 (layout) turns a logistical challenge into a strategic asset.
Investment Implications: Assessing a State Pharma Giant’s Transformation
For institutional investors and fund managers tracking Chinese healthcare, Guangzhou Pharmaceutical’s announcements warrant close scrutiny. The company is executing a high-risk, high-reward pivot that could redefine its valuation multiples.
The Upside: Capturing Dual Growth Vectors
The potential rewards are substantial. Success in the nuclear medicine track would grant entry into a global market projected to grow at a double-digit CAGR, driven by an aging population and advancements in precision oncology. Simultaneously, systematizing TCM出海 unlocks recurring revenue streams from emerging markets with growing middle classes. The company’s integrated model, backed by state support and strategic partnerships, provides a level of execution certainty that pure-play biotech startups often lack.
- Market Leadership: First-mover advantage in domestic nuclear medicine distribution and isotope sourcing.
- Pipeline Diversification: A future portfolio spanning TCM, generics, radiopharmaceuticals, and gene therapies.
- Policy Tailwinds: Direct alignment with national strategic priorities in healthcare self-sufficiency and Greater Bay Area integration.
The Risks: Execution Hurdles and Competitive Onslaught
However, the path is fraught with challenges. The nuclear medicine track is R&D-intensive and capital-hungry. Global giants like Novartis, with its marketed therapies Lutathera and Pluvicto, have a multi-year head start. Regulatory approval for novel radiopharmaceuticals in China and abroad remains a protracted process. Furthermore, the TCM出海 model, while innovative, still must overcome deeply ingrained skepticism in Western medical establishments. Execution risk on the massive Hengqin investment is non-trivial.
Investors should monitor key milestones: the completion of the Hengqin center, regulatory submissions for the first proprietary nuclear medicine asset, and the scale-up of CGT projects from the transfer center. The company’s ability to manage the cultural and operational integration of its various partnerships will also be critical.
Charting the Course from Traditional Giant to Global Innovator
Chen Jiehui’s vision for Guangzhou Pharmaceutical is unequivocal: a transition from a traditional pharmaceutical enterprise to an innovation-driven, globally oriented life sciences leader. The concurrent push on the nuclear medicine track and the TCM出海 front is not a dilution of focus but a calculated bet on complementary strengths. The nuclear medicine endeavor builds new, high-margin capabilities, while the TCM strategy modernizes and globalizes the existing cash-generating core.
The “15th Five-Year Plan” period (2026-2030) will be the ultimate proving ground. Success metrics will include international revenue share, the number of globally approved novel drugs, and the profit contribution from the nuclear medicine and CGT segments. The company’s willingness to invest billions and forge global partnerships indicates a serious commitment to this transformation.
For the international investment community, Guangzhou Pharmaceutical’s strategy offers a compelling lens through which to assess the maturation of China’s biopharma innovation ecosystem. It demonstrates how established players are leveraging domestic resources, policy advantages, and global collaboration to compete at the highest levels. The journey to achieve global parallel in the nuclear medicine track is arduous, but the blueprint is now clear. Market participants would be prudent to track the company’s progress closely, as its success or failure will have ripple effects across the sector, influencing capital flows and strategic partnerships for years to come. The call to action for investors is clear: scrutinize the upcoming operational milestones from Hengqin and the nuclear medicine pipeline, as they will be the true indicators of whether this ambitious dual strategy can deliver sustainable, high-value growth.